EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-Definition Brain Network (HDBN) Delineation of CDKL5 Deficiency Disorder (CDD) in Genetically Engineered Mice

Dalton West iD, Noah William Coulson, Devin Raine Everaldo Cortes iD, Kristina Elsa Schwab, Thomas Becker-Szurszewski iD, Sean Hartwick iD, Margaret Caroline Stapleton iD, Gabriella Marie Saladino, Cecilia Wen-Ya Lo iD, Christina M Patterson iD, Subramanian Subramanian iD, Deepa Soundara Rajan und 1 weitere

Biomolecules · 28.04.2026 · 16 (5) · 652

DOI: 10.3390/biom16050652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 28.04.2026. Verfasst von Dalton West und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA. Hauptthemen laut MEDLINE: Spasms, Infantile, Protein Serine-Threonine Kinases, Epileptic Syndromes, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH Common Fund, American Heart Association, United States Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficient Disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterized by early-onset refractory epilepsy, severe neurodevelopmental impairment, and lifelong disability. Although more than thirty anti-seizure medications are available, most CDD patients remain pharmaco-resistant. Gene-based therapies are emerging, but therapeutic development is hindered by marked clinical heterogeneity, small patient populations, and the lack of robust, translatable brain-based biomarkers for clinical trials. Genetically engineered Cdkl5 mouse models recapitulate many cognitive, behavioral, and molecular features of CDD, yet their utility is limited by the absence of overt seizures, precluding seizure-based outcome measures. Here, we establish high-definition brain network (HDBN) biomarkers using advanced diffusion MRI tractography combined with graph-theoretical analysis to quantify whole-brain network organization in Cdkl5 knockout mice. Diffusion MRI enables non-invasive mapping of axonal connectivity by leveraging anisotropic water diffusion, while high-angular-resolution acquisition overcomes key limitations of conventional diffusion tensor imaging in regions with complex fiber architecture. We demonstrate that Cdkl5 knockout mice exhibit reproducible and region-specific disruptions in brain network organization, prominently affecting the somatosensory and somatomotor cortex, hippocampus, hypothalamus, amygdala, and superior colliculus—regions implicated in cognition, learning and memory, homeostasis, anxiety, and visual–motor function. In contrast, networks within the entorhinal cortex remain largely preserved. These findings identify HDBN metrics as sensitive, non-invasive biomarkers that capture clinically relevant circuit-level abnormalities in CDD. Because diffusion MRI–based network analyses are directly translatable across species, HDBN biomarkers provide a unified framework for therapeutic evaluation in mouse models, large animals, and human clinical trials, enabling longitudinal monitoring of disease progression and treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spasms, InfantileProtein Serine-Threonine KinasesEpileptic SyndromesBrainNerve NetAnimalsMiceDisease Models, AnimalMice, KnockoutDiffusion Tensor ImagingMaleGenetic Engineering

Stichwörter der Autor:innen

CDDCDKL5MRIbrain networkdiffusion tensor imagingneurodevelopment

Substanzen

Protein Serine-Threonine KinasesCDKL5 protein, mouse

Autor:innen und Institutionen

  • Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA.
  • Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Animal Imaging Core, Rangos Research Center, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
  • UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
  • Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.

ORCID-Profile: Dalton West, Devin Raine Everaldo Cortes, Thomas Becker-Szurszewski, Sean Hartwick, Margaret Caroline Stapleton, Cecilia Wen-Ya Lo, Christina M Patterson, Subramanian Subramanian, Yijen Lin Wu

Förderung

  • NIH Common Fund
  • American Heart Association
  • United States Department of Defense
  • NIH

Zitieren

APA

West, D., Coulson, N. W., Cortes, D. R. E., Schwab, K. E., Becker-Szurszewski, T., Hartwick, S., Stapleton, M. C., Saladino, G. M., Lo, C. W., Patterson, C. M., Subramanian, S., Rajan, D. S., & Wu, Y. L. (2026). High-Definition Brain Network (HDBN) Delineation of CDKL5 Deficiency Disorder (CDD) in Genetically Engineered Mice. Biomolecules, 16(5), 652. https://doi.org/10.3390/biom16050652

Vancouver

West D, Coulson NW, Cortes DRE, Schwab KE, Becker-Szurszewski T, Hartwick S, et al. High-Definition Brain Network (HDBN) Delineation of CDKL5 Deficiency Disorder (CDD) in Genetically Engineered Mice. Biomolecules. 2026;16(5):652. doi:10.3390/biom16050652

BibTeX
@article{West2026,
  author = {West, Dalton and Coulson, Noah William and Cortes, Devin Raine Everaldo and Schwab, Kristina Elsa and Becker-Szurszewski, Thomas and Hartwick, Sean and Stapleton, Margaret Caroline and Saladino, Gabriella Marie and Lo, Cecilia Wen-Ya and Patterson, Christina M and Subramanian, Subramanian and Rajan, Deepa Soundara and Wu, Yijen Lin},
  title = {High-Definition Brain Network (HDBN) Delineation of CDKL5 Deficiency Disorder (CDD) in Genetically Engineered Mice},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {652},
  doi = {10.3390/biom16050652}
}
Kostenlos starten →